IPO Journey
Odyssey Therapeutics, Inc.
IPO Date: May 8, 2026 · 3 filings tracked
Final Offer Terms
Ticker
ODTX
Exchange
Nasdaq Capital Market
Offer Price
$18.00
Shares Offered
15,500,000
Estimated Proceeds
$279.0M
Expected Listing
May 11, 2026
Underwriters
Led by J.P. Morgan, TD Cowen
CantorWedbush PacGrowOppenheimer & Co.
Filing Timeline
1
S-1
April 17, 2026
- Proprietary platform combining AI, structural biology, and chemistry to target 'undruggable' proteins.
- Focus on oral, precision medicines for autoimmune conditions like lupus and IBD.
2
S-1/A
May 4, 2026
- Advanced drug discovery engine targeting 'undruggable' proteins
- Precision medicine focus on cancer and inflammatory diseases
Changes from previous filing
- ▸ Ticker symbol: ODTX
- ▸ Expected offer range: $16.0 – $18.0 per share
- ▸ Shares offered: 13,240,000
- ▸ Estimated proceeds: $211M
424B4
Final Pricing
May 8, 2026
- Focuses on 'undruggable' protein targets for autoimmune and inflammatory diseases
- Lead candidate OD-001 targets RIPK2 to address treatment-resistant inflammation
Changes from previous filing
- ▸ Price range removed
- ▸ Final offer price: $18.0 per share
- ▸ Shares offered: 15,500,000
- ▸ Estimated proceeds: $279M
- ▸ Underwriters: J.P. Morgan, TD Cowen, Cantor, Wedbush PacGrow, Oppenheimer & Co.
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.